BlissBio, founded in December 2017, has developed into a clinical-stage biotech company dedicated to the discovery, development and commercialization of oncology biological therapeutics. BlissBio currently has multiple innovative tumor-targeting ADCs in Phase I and Phase II clinical trials, all of which have broad market prospects for a variety of oncology indications. The core team of BlissBio has a successful track record in the development of multiple biotherapeutics in this field, has developed several technology platforms as well as a rich pipeline with the products at different stages, and has the capability to manufacture antibodies and ADCs that meet international GMP standards in its own facility. Through international collaborations, BlissBio works closely with partners to jointly promote the advancement of differentiated innovative biotherapeutics with global competitiveness.